MRS2500 [2-Iodo-N6-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate], a Potent, Selective, and Stable Antagonist of the Platelet P2Y1Receptor with Strong Antithrombotic Activity in Mice
- 19 October 2005
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 316 (2), 556-563
- https://doi.org/10.1124/jpet.105.094037
Abstract
The platelet P2Y1 ADP receptor is an attractive target for new antiplatelet drugs. However, because of the lack of strong and stable antagonists, only a few studies have suggested that pharmacological inhibition of the P2Y1 receptor could efficiently inhibit experimental thrombosis in vivo. Our aim was to determine whether the newly described potent and selective P2Y1 receptor antagonist MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate] could inhibit platelet function ex vivo and experimental thrombosis in mice in vivo. MRS2500 was injected intravenously into mice, and its effect on ex vivo platelet aggregation and in several models of thrombosis in vivo was determined. MRS2500 displayed high potency and stable and selective P2Y1 receptor inhibition ex vivo. Although MRS2500 injection resulted in only moderate prolongation of the bleeding time, it provided strong protection in systemic thromboembolism induced by infusion of a mixture of collagen and adrenaline. MRS2500 also potently inhibited localized arterial thrombosis in a model of laser-induced vessel wall injury with two degrees of severity. Moreover, combination of MRS2500 with clopidogrel, the irreversible inhibitor of the platelet P2Y12 receptor for ADP, led to increased antithrombotic efficacy compared with each alone. These results add further evidence for a role of the P2Y1 receptor in thrombosis and validate the concept that targeting the P2Y1 receptor could be a relevant alternative or complement to current antiplatelet strategies.Keywords
This publication has 33 references indexed in Scilit:
- Importance of Platelet Phospholipase Cγ2 Signaling in Arterial Thrombosis as a Function of Lesion SeverityArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Preclinical and Clinical Studies with Selective Reversible Direct P2Y12AntagonistsSeminars in Thrombosis and Hemostasis, 2005
- Pharmacology of CS-747 (prasugrel, LY640315), a Novel, Potent Antiplatelet Agent with in Vivo P2Y12Receptor Antagonist ActivitySeminars in Thrombosis and Hemostasis, 2005
- Clopidogrel and Ticlopidine: P2Y12Adenosine Diphosphate-Receptor Antagonists for the Prevention of AtherothrombosisSeminars in Thrombosis and Hemostasis, 2005
- Molecular Recognition at Adenine Nucleotide (P2) Receptors in PlateletsSeminars in Thrombosis and Hemostasis, 2005
- The Platelet P2 Receptors in ThrombosisSeminars in Thrombosis and Hemostasis, 2005
- Inhibition of Platelet Functions and Thrombosis through Selective or Nonselective Inhibition of the Platelet P2 Receptors with Increasing Doses of NF449 [4,4′,4″,4″′-(Carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic Acid Octasodium Salt]Journal of Pharmacology and Experimental Therapeutics, 2005
- Differential Involvement of the P2Y 1 and P2Y 12 Receptors in Platelet Procoagulant ActivityArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- A Role of the Fast ATP-gated P2X1 Cation Channel in Thrombosis of Small Arteries In VivoThe Journal of Experimental Medicine, 2003
- The P2Y12 receptor induces platelet aggregation through weak activation of the αIIbβ3 integrin – a phosphoinositide 3‐kinase‐dependent mechanismFEBS Letters, 2001